Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-235720
Filing Date
2025-10-09
Accepted
2025-10-09 15:04:21
Documents
71
Period of Report
2025-08-31

Document Format Files

Seq Description Document Type Size
1 10-Q neog-20250831.htm   iXBRL 10-Q 1706400
2 EX-10.1 neog-ex10_1.htm EX-10.1 50826
3 EX-10.2 neog-ex10_2.htm EX-10.2 28935
4 EX-10.3 neog-ex10_3.htm EX-10.3 34971
5 EX-10.4 neog-ex10_4.htm EX-10.4 52863
6 EX-10.5 neog-ex10_5.htm EX-10.5 35775
7 EX-31.1 neog-ex31_1.htm EX-31.1 15775
8 EX-31.2 neog-ex31_2.htm EX-31.2 15566
9 EX-32 neog-ex32.htm EX-32 12837
10 GRAPHIC img192722933_0.jpg GRAPHIC 55106
11 GRAPHIC img194660645_0.jpg GRAPHIC 646845
12 GRAPHIC img195493496_0.jpg GRAPHIC 55106
  Complete submission text file 0001193125-25-235720.txt   9734818

Data Files

Seq Description Document Type Size
13 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT neog-20250831.xsd EX-101.SCH 1323670
73 EXTRACTED XBRL INSTANCE DOCUMENT neog-20250831_htm.xml XML 1302732
Mailing Address 620 LESHER PLACE LANSING MI 48912
Business Address 620 LESHER PLACE LANSING MI 48912 5173729200
NEOGEN CORP (Filer) CIK: 0000711377 (see all company filings)

EIN.: 382367843 | State of Incorp.: MI | Fiscal Year End: 0531
Type: 10-Q | Act: 34 | File No.: 000-17988 | Film No.: 251384759
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)